CN110526914B - A kind of polymorph of ALK inhibitor and preparation method thereof - Google Patents

A kind of polymorph of ALK inhibitor and preparation method thereof Download PDF

Info

Publication number
CN110526914B
CN110526914B CN201810520684.6A CN201810520684A CN110526914B CN 110526914 B CN110526914 B CN 110526914B CN 201810520684 A CN201810520684 A CN 201810520684A CN 110526914 B CN110526914 B CN 110526914B
Authority
CN
China
Prior art keywords
polymorph
pyrimidine
pyrrolo
piperidin
dimethylamino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201810520684.6A
Other languages
Chinese (zh)
Other versions
CN110526914A (en
Inventor
冀冲
孙德广
杨利民
史建龙
王再全
佟鹤芳
张传玉
王红瑞
李毅
陈岩
杨嘉铭
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Capital Pharmaceutical Holdings Beijing Co ltd
Original Assignee
Capital Pharmaceutical Holdings Beijing Co ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Capital Pharmaceutical Holdings Beijing Co ltd filed Critical Capital Pharmaceutical Holdings Beijing Co ltd
Priority to CN201810520684.6A priority Critical patent/CN110526914B/en
Publication of CN110526914A publication Critical patent/CN110526914A/en
Application granted granted Critical
Publication of CN110526914B publication Critical patent/CN110526914B/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

本发明涉及N2‑(4‑(4‑(二甲胺基)哌啶‑1‑基)‑2‑甲氧基苯基)‑N4‑(2‑(异丙基磺酰基)苯基)‑7H‑吡咯并[2，3‑d]嘧啶‑2，4‑二胺的多晶型物及其制备方法。

Figure DSA0000164482650000011
The present invention relates to N 2 -(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)-N 4 -(2-(isopropylsulfonyl)phenyl) )-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine polymorph and preparation method thereof.
Figure DSA0000164482650000011

Description

Polymorphic substance of ALK inhibitor and preparation method thereof
Technical Field
The invention relates to an ALK inhibitor polymorphism, in particular to N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorphs of pyrimidine-2, 4-diamine and methods for their preparation.
Background
N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine is a high-selectivity small-molecule ALK tyrosine kinase inhibitor, has the inhibitory effect on ALK tyrosine kinase at the cellular level with nanomolar effect intensity, has complete inhibitory effect on the tumor growth of non-small cell lung cancer and lymphoma caused by abnormal high expression of ALK fusion protein in animal bodies, and N is2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Pyrimidine-2, 4-diamine resistance to the currently clinically leading same ALK inhibitor crizotinibThe ALK kinase mutant subtype with closely related medicinal properties has a remarkable inhibiting effect, and the structural formula is as follows:
Figure BSA0000164482670000011
the synthetic method of the compound is disclosed in Chinese patent application 201710009761.7, but the crystal form condition of the compound is not involved, and no other literature reports N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]A crystalline form of pyrimidine-2, 4-diamine. The polymorphism of the medicine has important significance on the physical properties, bioavailability, quality and process of the preparation, the difference of physicochemical properties among different crystal forms of the polymorphism medicine influences the stability of the medicine, and the bioavailability may have obvious difference when the same medicine has different crystal forms. Different crystal forms affect the dissolution rate of the drug, and the difference of surface free energy of different crystal forms can cause different bonding force among crystal particles, and affect the fluidity, particle uniformity, content uniformity and physical stability of the drug. Therefore, research on its crystal form is required.
Drawings
Figure 1 is an X-ray powder diffraction pattern of polymorph a.
Figure 2 is an X-ray powder diffraction pattern of polymorph B.
Figure 3 is an X-ray powder diffraction pattern of polymorph C.
Figure 4 is an X-ray powder diffraction pattern of polymorph D.
Figure 5 is an X-ray powder diffraction pattern of polymorph E.
Figure 6 is a DSC profile of polymorph a.
Figure 7 is a DSC profile of polymorph B.
Figure 8 is a DSC profile of polymorph C.
Figure 9 is a DSC profile of polymorph D.
Figure 10 is a TGA profile of polymorph D.
Disclosure of Invention
The invention relates toAnd N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorphic form A, B, C, D, E of pyrimidine-2, 4-diamine and a process for its preparation.
The invention relates to N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph form A of pyrimidine-2, 4-diamine, crystalline form N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine has an X-ray powder diffraction pattern as shown in figure 1, the measurement error of 2 theta is +/-0.10 degrees, and a plurality of characteristic peaks between 0 and 50 degrees are shown in table 1.
Table 1: 2 theta Angle and d-value of polymorph A
2 theta angle d- Relative strength
5.002 17.667 100.00
7.113 12.427 31.71
11.151 7.935 49.19
15.416 5.748 30.37
15.816 5.604 26.02
16.046 5.524 44.23
18.091 4.904 12.60
19.028 4.664 38.64
20.167 4.403 12.29
21.526 4.128 13.72
22.734 3.912 10.99
25.422 3.504 32.37
25.927 3.437 15.67
The invention relates to N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph form B of pyrimidine-2, 4-diamine, crystalline form N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine has an X-ray powder diffraction pattern as shown in figure 2, the measurement error of 2 theta is +/-0.10 degrees, and a plurality of characteristic peaks between 0 and 50 degrees are shown in table 2.
Table 2: 2 theta Angle and d-value of polymorph B
2 theta angle d- Relative strength
6.951 12.717 100.00
7.101 12.450 63.11
11.915 7.428 47.42
12.222 7.242 34.19
14.416 6.144 17.43
14.797 5.987 24.24
15.186 5.835 94.80
15.457 5.733 10.77
17.285 5.131 10.10
17.566 5.049 44.88
18.197 4.875 32.93
18.670 4.753 46.37
20.178 4.401 53.32
20.602 4.311 31.62
21.077 4.215 54.15
21.568 4.120 22.90
22.135 4.016 10.90
23.124 3.846 22.93
23.820 3.736 23.41
24.578 3.622 34.31
24.912 3.574 22.08
26.532 3.360 20.51
28.150 3.170 13.72
The invention relates to N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph form C of pyrimidine-2, 4-diamine, crystalline form N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine has an X-ray powder diffraction pattern as shown in FIG. 3, the measurement error of 2 theta is +/-0.10 degrees, and a plurality of characteristic peaks between 0 and 50 degrees are shown in Table 3.
Table 3: 2 theta Angle and d-value of polymorph C
2θ d-value Relative strength
5.0186 17.60888 100.00
6.5079 13.58204 11.70
9.7245 9.09545 22.34
11.1230 7.95487 17.93
13.1441 6.73585 11.96
15.4008 5.75355 15.89
15.7390 5.63067 28.64
16.0408 5.52541 14.36
18.9815 4.67550 14.01
19.4420 4.56579 16.31
25.3748 3.51013 14.74
The invention relates to N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph form D of pyrimidine-2, 4-diamine, crystalline form N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropyl) isopropyl alcoholPhenylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine has an X-ray powder diffraction pattern as shown in FIG. 4, the measurement error of 2 theta is +/-0.10 degrees, and a plurality of characteristic peaks between 0 and 50 degrees are shown in Table 4.
Table 4: 2 theta Angle and D-value of polymorph D
Figure BSA0000164482670000051
Figure BSA0000164482670000061
The invention relates to N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph form E of pyrimidine-2, 4-diamine, crystalline form N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine has an X-ray powder diffraction pattern as shown in FIG. 5, and has a measurement error of 2 theta of + -0.10 degrees and a plurality of characteristic peaks between 0 and 50 degrees as shown in Table 5.
Table 5: 2 theta Angle and d-value of polymorph E
Figure BSA0000164482670000062
Figure BSA0000164482670000071
The numerical relative intensities in the seven tables above are defined in the following table:
relative strength Definition of
80-100 VS (very strong)
60-80 S (Strong)
40-60 M (middle)
10-40 W (Weak)
The invention also provides N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Process for the preparation of pyrimidine-2, 4-diamine polymorphs A, B, C, D and E, N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine is synthesized according to the method of patent Chinese patent application 201710009761.7, and the preparation methods of the five polymorphic forms are all N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine is recrystallized in different solvents or crystallized by heating in water.
The polymorphic form A is prepared by reacting N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Heating and dissolving the pyrimidine-2, 4-diamine in n-propanol and acetonitrile, and standing for crystallization.
The polymorphic form B is prepared by reacting N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Dissolving pyrimidine-2, 4-diamine in the solvent of diStanding in the hexachloro-oxygen ring for crystallization, wherein the crystal is a dioxane solvate of the compound.
The polymorphic form C is prepared by reacting N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The polymorphic substance A or the polymorphic substance B of the pyrimidine-2, 4-diamine is heated, stirred and crystallized in water.
The polymorphic form D is prepared by reacting N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Heating and dissolving pyrimidine-2, 4-diamine in n-propanol and acetonitrile, and stirring for crystallization, or heating and dissolving pyrimidine-2, 4-diamine in n-propanol and ethyl acetate, and stirring for crystallization.
The polymorphic substance E is prepared by reacting N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Dissolving pyrimidine-2, 4-diamine in n-propanol, standing for crystallization, and obtaining the crystal as an n-propanol solvate of the compound.
The processes for the preparation of polymorphic forms A, B, C, D and E are followed by crystallization, filtration and vacuum drying to remove solvent or water.
The polymorphic form D can be obtained by recrystallization from N-propanol and acetonitrile, or from N-propanol and ethyl acetate, and the product obtained by recrystallization from two solvent systems is subjected to X-ray powder diffraction pattern analysis, the different numbers of 2 theta angles are less than one third, and both contain the characteristic peaks listed in Table 1, so that the N obtained by recrystallization from two solvent systems is considered2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]The pyrimidine-2, 4-diamine belongs to the same crystal form.
The invention discovers N through experiments2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Pyrimidine-2, 4-diamine exists as polymorphs A, B, C, D and E. The five polymorphs are subjected to a crystal form transformation experiment, and show that the stability of the polymorph D is good, and the stability of other polymorphs is poor.
The present invention will be described in further detail with reference to examples of specific embodiments.
Examples 1, N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Preparation of pyrimidine-2, 4-diamine polymorph A
Reacting compound N at room temperature2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N2- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Adding pyrimidine-2, 4-diamine (50.0g), n-propanol (250mL) and acetonitrile (250mL) into a 1000mL single-neck flask, heating to 85 ℃ at the internal temperature under the protection of nitrogen, adjusting the temperature to 25 ℃ after all solids are dissolved, standing for crystallization, performing suction filtration, and performing vacuum drying at 30 ℃ overnight to obtain 35.0g of white needle-like solid, wherein the yield is as follows: 70.0 percent.
DSC graphs (onset temperature 25 ℃, end temperature 250 ℃, heating rate 10 ℃/min) are shown in FIG. 6.
Example 2, N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Preparation of pyrimidine-2, 4-amine polymorph B
Reacting compound N at room temperature2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Adding pyrimidine-2, 4-diamine (1.05g) and 1, 4-oxohexacyclic ring (15mL) into a 50mL single-neck flask, heating to 75 ℃ at the internal temperature under the protection of nitrogen, reducing the temperature to 25 ℃ after all solids are dissolved, standing for crystallization, performing suction filtration, and performing vacuum drying at 30 ℃ overnight to obtain 0.67g of light yellow granular solid, wherein the yield is as follows: 67.0 percent.
DSC graphs (onset temperature 25 ℃, end temperature 250 ℃, heating rate 10 ℃/min)) are shown in FIG. 7.
Example 3, N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Preparation of pyrimidine-2, 4-diamine polymorph C
Reacting compound N at room temperature2-(4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph a (250mg), polymorph B (250mg) and purified water (50mL) of pyrimidine-2, 4-diamine were added to a 100mL single-neck flask, heated to an internal temperature of 50 ℃, stirred for 5 days, cooled to room temperature, filtered with suction, and vacuum-dried overnight at 30 ℃ to give 0.4g of a pale yellow solid, yield: 80.0 percent.
DSC graphs (onset temperature 25 ℃, end temperature 250 ℃, heating rate 10 ℃/min) are shown in FIG. 8.
Example 4, N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Preparation of pyrimidine-2, 4-diamine polymorph D
Reacting compound N at room temperature2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Adding pyrimidine-2, 4-diamine (60.0g), n-propanol (300mL) and acetonitrile (300mL) into a 1000mL single-neck flask, heating to 85 ℃ at the internal temperature under the protection of nitrogen, reducing the temperature to 25 ℃ after all solids are dissolved, stirring for crystallization, carrying out suction filtration, and carrying out vacuum drying at 30 ℃ overnight to obtain 47.1g of light yellow needle granular solid, wherein the yield is as follows: 78.5 percent.
DSC graphs (onset temperature 25 ℃, end temperature 250 ℃, heating rate 10 ℃/min) are shown in FIG. 9.
The TGA profile (start temperature 25 deg.C, end temperature 250 deg.C, heating rate 10 deg.C/min) is shown in FIG. 10.
Example 5, N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Preparation of pyrimidine-2, 4-diamine polymorph E
Reacting compound N at room temperature2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Adding pyrimidine-2, 4-diamine (1.0g) and n-propanol (30mL) into a 100mL single-neck flask, heating to an internal temperature of 97 ℃ under the protection of nitrogen, reducing the temperature to 25 ℃ after all solids are dissolved, standing and precipitatingThe crystals were filtered with suction and dried overnight under vacuum at 30 ℃ to give a pale yellow granular solid 0.72g, yield: 72.0 percent.
Example 6, N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph a and polymorph D of pyrimidine-2, 4-diamine.
Reacting compound N at room temperature2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph a (500mg), polymorph D (500mg) and purified water (70mL) of pyrimidine-2, 4-diamine were added to a 250mL single-neck flask, heated to an internal temperature of 50 ℃, stirred for 5 days, cooled to room temperature, filtered with suction, and vacuum-dried overnight at 30 ℃ to give 0.8g of a pale yellow solid, yield: 80.0 percent.
The solid above was sent to X-ray powder diffraction and the results indicated the conversion of polymorph a to polymorph D.
Example 7, N2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N4- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph C and polymorph D of pyrimidine-2, 4-diamine.
Reacting compound N at room temperature2- (4- (4- (dimethylamino) piperidin-1-yl) -2-methoxyphenyl) -N2- (2- (isopropylsulfonyl) phenyl) -7H-pyrrolo [2, 3-d]Polymorph C (200mg), polymorph D (200mg) and purified water (50mL) of pyrimidine-2, 4-diamine were added to a 100mL single-neck flask, heated to an internal temperature of 50 ℃, stirred for 5 days, cooled to room temperature, filtered with suction, and vacuum-dried overnight at 30 ℃ to give 0.3g of a pale yellow solid, yield: 75.0 percent.
The solid above was sent to X-ray powder diffraction and the results indicated the conversion of polymorph C to polymorph D.
The results show that the stability of the polymorphic form D is good, and the stability of other forms is poor.

Claims (15)

1.N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺的多晶型物A，其特征在于，其在208±3℃熔化，X射线粉末衍射图在以2θ表示的以下位置有特征峰：5.002，7.113，11.151，15.417，15.816，16.045，19.028，25.422。1. N 2 -(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl)-N 4 -(2-(isopropylsulfonyl)phenyl) - Polymorph A of 7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, characterized in that it melts at 208±3°C and has an X-ray powder diffraction pattern in 2θ below The positions have characteristic peaks: 5.002, 7.113, 11.151, 15.417, 15.816, 16.045, 19.028, 25.422. 2.根据权利要求1所述的多晶型物A，其特征在于，X射线粉末衍射图，如图1所示。2 . The polymorph A according to claim 1 , wherein the X-ray powder diffraction pattern is as shown in FIG. 1 . 3 . 3.权利要求1或2的多晶型物A的制备方法，其特征在于，N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺加热溶于正丙醇和乙腈中，然后静置结晶得到多晶型物A。3. The preparation method of polymorph A according to claim 1 or 2, characterized in that N 2 -(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxybenzene base)-N 4 -(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine was dissolved in n-propanol and acetonitrile by heating, and then Crystallization yields polymorph A. 4.N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺的多晶型物B，其特征在于，X射线粉末衍射图在以2θ表示的以下位置有特征峰：6.951，7.101，11.915，12.222，15.186，17.566，18.670，20.178，21.077，24.578。4. N2- (4-(4-(dimethylamino)piperidin- 1 -yl)-2-methoxyphenyl)-N4-(2-(isopropylsulfonyl)phenyl) -Polymorph B of 7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, characterized in that the X-ray powder diffraction pattern has characteristic peaks at the following positions expressed in 2θ: 6.951, 7.101 , 11.915, 12.222, 15.186, 17.566, 18.670, 20.178, 21.077, 24.578. 5.根据权利要求4所述的多晶型物B，其特征在于，X射线粉末衍射图，如图2所示。5 . The polymorph B according to claim 4 , wherein the X-ray powder diffraction pattern is shown in FIG. 2 . 6 . 6.权利要求4或5的多晶型物B的制备方法，其特征在于，N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺加热溶于二氧六环中，然后静置结晶得到多晶型物B，核磁氢谱证实为1∶1溶剂合物。6. The preparation method of polymorph B according to claim 4 or 5, characterized in that N 2 -(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxybenzene base)-N 4 -(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine was dissolved in dioxane by heating, and then It was crystallized to obtain polymorph B, which was confirmed to be a 1:1 solvate by proton NMR. 7.N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺的多晶型物C，其特征在于，X射线粉末衍射图在以2θ表示的以下位置有特征峰：5.019，9.725，11.123，15.401，15.739，18.982，19.442，25.375，25.820。7. N2- (4-(4-(dimethylamino)piperidin- 1 -yl)-2-methoxyphenyl)-N4-(2-(isopropylsulfonyl)phenyl) - Polymorph C of 7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, characterized in that the X-ray powder diffraction pattern has characteristic peaks at the following positions expressed in 2θ: 5.019, 9.725 , 11.123, 15.401, 15.739, 18.982, 19.442, 25.375, 25.820. 8.根据权利要求7所述的多晶型物C，其特征在于，X射线粉末衍射图，如图3所示。8 . The polymorph C according to claim 7 , wherein the X-ray powder diffraction pattern is shown in FIG. 3 . 9.权利要求7或8的多晶型物C的制备方法，其特征在于，N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺的多晶型物A和多晶型物B在水中加热搅拌转晶得到多晶型物C。9. The preparation method of polymorph C according to claim 7 or 8, characterized in that N 2 -(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxybenzene yl)-N4-(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3- d ]pyrimidine-2,4-diamine polymorph A and polymorph B is heated and stirred in water and crystallized to obtain polymorph C. 10.N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺的多晶型物D，其特征在于，X射线粉末衍射图在以2θ表示的以下位置有特征峰：8.533，15.779，16.052，16.313，17.114，17.374，18.631，24.171。10. N2- (4-(4-(dimethylamino)piperidin- 1 -yl)-2-methoxyphenyl)-N4-(2-(isopropylsulfonyl)phenyl) Polymorph D of -7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, characterized by an X-ray powder diffraction pattern with characteristic peaks at the following positions expressed in 2θ: 8.533, 15.779 , 16.052, 16.313, 17.114, 17.374, 18.631, 24.171. 11.根据权利要求10所述的多晶型物D，其特征在于，X射线粉末衍射图，如图4所示。11 . The polymorph D according to claim 10 , wherein the X-ray powder diffraction pattern is shown in FIG. 4 . 12.权利要求10或11的多晶型物D的制备方法，其特征在于，N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺溶于正丙醇和乙腈、或者正丙醇和乙酸乙酯中，然后静置结晶得到多晶型物D。12. The preparation method of polymorph D according to claim 10 or 11, characterized in that N 2 -(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxybenzene base)-N 4 -(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine dissolved in n-propanol and acetonitrile, or n-propanol and ethyl acetate, followed by crystallization on standing to give polymorph D. 13.N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺的多晶型物E，其特征在于，X射线粉末衍射图在以2θ表示的以下位置有特征峰：6.355，6.592，10.836，11.160，13.284，13.672，15.405，15.831，20.328，23.344，23.482。13. N2- (4-(4-(dimethylamino)piperidin- 1 -yl)-2-methoxyphenyl)-N4-(2-(isopropylsulfonyl)phenyl) Polymorph E of -7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine, characterized by an X-ray powder diffraction pattern with characteristic peaks at the following positions expressed in 2θ: 6.355, 6.592 , 10.836, 11.160, 13.284, 13.672, 15.405, 15.831, 20.328, 23.344, 23.482. 14.根据权利要求13所述的多晶型物E，其特征在于，X射线粉末衍射图，如图5所示。14 . The polymorph E according to claim 13 , wherein the X-ray powder diffraction pattern is shown in FIG. 5 . 15.权利要求14的多晶型物E的制备方法，其特征在于，N2-(4-(4-(二甲胺基)哌啶-1-基)-2-甲氧基苯基)-N4-(2-(异丙基磺酰基)苯基)-7H-吡咯并[2，3-d]嘧啶-2，4-二胺溶于正丙醇中，然后静置结晶得到多晶型物E，核磁氢谱证实为1∶1溶剂合物。15. The preparation method of polymorph E according to claim 14, characterized in that N 2 -(4-(4-(dimethylamino)piperidin-1-yl)-2-methoxyphenyl) -N 4 -(2-(isopropylsulfonyl)phenyl)-7H-pyrrolo[2,3-d]pyrimidine-2,4-diamine was dissolved in n-propanol, and then crystallized by standing to obtain poly Form E was confirmed to be a 1:1 solvate by proton NMR.
CN201810520684.6A 2018-05-25 2018-05-25 A kind of polymorph of ALK inhibitor and preparation method thereof Active CN110526914B (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201810520684.6A CN110526914B (en) 2018-05-25 2018-05-25 A kind of polymorph of ALK inhibitor and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201810520684.6A CN110526914B (en) 2018-05-25 2018-05-25 A kind of polymorph of ALK inhibitor and preparation method thereof

Publications (2)

Publication Number Publication Date
CN110526914A CN110526914A (en) 2019-12-03
CN110526914B true CN110526914B (en) 2022-02-08

Family

ID=68657926

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201810520684.6A Active CN110526914B (en) 2018-05-25 2018-05-25 A kind of polymorph of ALK inhibitor and preparation method thereof

Country Status (1)

Country Link
CN (1) CN110526914B (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4484430A4 (en) * 2022-02-24 2026-04-15 Prime Gene Therapeutics Co Ltd POLYMORPH OF A JAK-TYROSINE KINASE Inhibitor AND MANUFACTURING METHOD THEREFINE
US20260034133A1 (en) * 2023-03-10 2026-02-05 Shouyao Holdings (beijing) Co., Ltd. Use of pharmaceutical compound in the treatment of solid tumors
EP4691458A1 (en) * 2023-03-24 2026-02-11 Shouyao Holdings (Beijing) Co., Ltd. Self-microemulsion pharmaceutical preparation composition containing alk kinase inhibitor and preparation method therefor
TW202508595A (en) 2023-05-04 2025-03-01 美商銳新醫藥公司 Combination therapy for a ras related disease or disorder
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
TW202547461A (en) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ras inhibitors
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476776A (en) * 2011-01-07 2013-12-25 北京赛林泰医药技术有限公司 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
CN106188060A (en) * 2015-04-29 2016-12-07 厦门大学 Pyrimido azoles, its preparation method, Pharmaceutical composition and application thereof
CN107200741A (en) * 2016-03-16 2017-09-26 北京赛林泰医药技术有限公司 A kind of preparation method of anaplastic lymphoma kinase inhibitor
CN108276410A (en) * 2017-01-06 2018-07-13 北京赛林泰医药技术有限公司 A kind of anaplastic lymphoma kinase inhibitor and its preparation method and application

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103476776A (en) * 2011-01-07 2013-12-25 北京赛林泰医药技术有限公司 2,4-diamino-6,7-dihydro-5H-pyrrolo[2,3]pyrimidine derivatives as FAK/Pyk2 inhibitors
CN106188060A (en) * 2015-04-29 2016-12-07 厦门大学 Pyrimido azoles, its preparation method, Pharmaceutical composition and application thereof
CN107200741A (en) * 2016-03-16 2017-09-26 北京赛林泰医药技术有限公司 A kind of preparation method of anaplastic lymphoma kinase inhibitor
CN108276410A (en) * 2017-01-06 2018-07-13 北京赛林泰医药技术有限公司 A kind of anaplastic lymphoma kinase inhibitor and its preparation method and application

Also Published As

Publication number Publication date
CN110526914A (en) 2019-12-03

Similar Documents

Publication Publication Date Title
CN110526914B (en) A kind of polymorph of ALK inhibitor and preparation method thereof
US9309229B2 (en) Crystalline forms of 5-chloro-N2-(2-isopropoxy-5-methyl-4-piperidin-4-yl-phenyl)-N4-[2-(propane-2-sulfonyl)-phenyl]-pyrimidine-2, 4-diamine
US9895377B2 (en) Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
TWI597277B (en) Form i crystal of dimaleate salt of tyrosine kinase inhibitor and preparation method thereof
KR20170078710A (en) Crystal Form of JAK Kinase inhibitor Bisulfate and a preparation method therefor
CN105980389B (en) A crystalline form of bisulfate salt of JAK kinase inhibitor and its preparation method
CN106333952A (en) Crystallization form of thymidine phosphorylase inhibitor and preparation method thereof
WO2012150606A2 (en) A process for preparing stable polymophic form of erlotinib hydrochloride
WO2024109871A1 (en) Pharmaceutically acceptable salt of nitrogen-containing heterocyclic compound, crystal form thereof, and preparation method therefor
US10011591B2 (en) Crystalline form of afatinib dimaleate
WO2018157803A1 (en) Venetoclax crystal forms and preparation method therefor
CN105503854A (en) New crystal form substance of Dasatinib anhydrous substance and preparation method thereof
WO2018228205A1 (en) 2-[4-(methylaminomethyl)phenyl]-5-fluoro-benzofuran-7-carboxamide hydrochloride polymorph, preparation method therefor and application thereof
WO2012090221A1 (en) Novel salts of imatinib
CN111732586B (en) Crystal form, preparation method and application of alkynyl-containing compound salt
CN104163771A (en) Preparation method of Agomelatine crystal form I
WO2016110243A1 (en) Crystalline form of malate of tyrosine kinase inhibitor and preparation method therefor
CN114989172A (en) A kind of polymorph of tyrosine kinase inhibitor and preparation method thereof
CN108727381B (en) ALK tyrosine kinase inhibitor salt and preparation method thereof
CN104788435A (en) I-type crystal of dibenzenesulfonate of inhibitor of protein tyrosine kinase
WO2020119772A1 (en) Mefuparib hydrochloride polymorphic substance and preparation method therefor
CN111320568A (en) Novel crystal form of pimavanserin and preparation method thereof
CN113024543A (en) Polymorphic substance of Bcl-2 selective inhibitor salt and preparation method thereof
WO2019057165A1 (en) Crystal form of idarubicin hydrochloride monohydrate
CN116947825A (en) Crystal forms of FGFR4 selective inhibitor compound, preparation method and application thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
CB02 Change of applicant information
CB02 Change of applicant information

Address after: 100176 No. 2213, 2nd floor, building D, building 33, 99 Kechuang 14th Street, Beijing Economic and Technological Development Zone, Beijing (centralized office area)

Applicant after: Capital Pharmaceutical Holdings (Beijing) Co.,Ltd.

Address before: 100176 No. 2213, 2nd floor, building D, building 33, 99 Kechuang 14th Street, Beijing Economic and Technological Development Zone, Beijing (centralized office area)

Applicant before: Shouyao holding (Beijing) Co.,Ltd.

GR01 Patent grant
GR01 Patent grant